MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Memorial Hermann is laying off 83 employees due to the closure of the University Place senior living community and nursing ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

GET 6 MONTHS FREEIn a follow-up TikTok post on March 31, O'Donnell gave another shoutout to Mounjaro for its impact on her weight loss while reflecting on the financial limitations of the drug's ...

A Houston neurologist had his medical license suspended following his arrest on charges that accuse him of soliciting a minor ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...